Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer

BackgroundThe trastuzumab biosimilar CT-P6 has demonstrated equivalent efficacy and comparable safety to reference trastuzumab (RTZ) in clinical trials of human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC). Here, we present the first real-world comparison of CT-P6 ver...

Full description

Bibliographic Details
Main Authors:	Soong June Bae, Jee Hung Kim, Sung Gwe Ahn, Hei-Cheul Jeung, Joohyuk Sohn, Gun Min Kim, Min Hwan Kim, Seung Il Kim, Seho Park, Hyung Seok Park, Ji Ye Kim, Joon Jeong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-06-01
Series:	Frontiers in Oncology
Subjects:	biosimilar HER2-positive breast cancer trastuzumab CT-P6 early breast cancer (EBC) metastatic breast cancer (mbc)
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.689587/full

Similar Items

Association between Skeletal Muscle Loss and the Response to Neoadjuvant Chemotherapy for Breast Cancer
by: Byung Min Lee, et al.
Published: (2021-04-01)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
by: Jung Hwan Ji, et al.
Published: (2023-01-01)

Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer
by: Chang Ik Yoon, et al.
Published: (2020-07-01)

SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
by: Seung Ho Baek, et al.
Published: (2022-06-01)

YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
by: Inho Park, et al.
Published: (2023-10-01)

Radiation dose-event relationship after intraoperative radiotherapy as a boost in patients with breast cancer
by: Yeona Cho, et al.
Published: (2023-05-01)

Metastasis Risk Assessment Using BAG2 Expression by Cancer-Associated Fibroblast and Tumor Cells in Patients with Breast Cancer
by: Chang-Ik Yoon, et al.
Published: (2021-09-01)

The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy
by: Janghee Lee, et al.
Published: (2021-12-01)

Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B)
by: Sung Hoon Sim, et al.
Published: (2022-10-01)

Genomic Signature of the Standardized Uptake Value in <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography in Breast Cancer
by: Seon-Kyu Kim, et al.
Published: (2020-02-01)

Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade
by: Soong June Bae, et al.
Published: (2024-02-01)

Elasticity Values as a Predictive Modality for Response to Neoadjuvant Chemotherapy in Breast Cancer
by: Min Ji Kim, et al.
Published: (2024-01-01)

Optimal treatment strategy for hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer patients with 1–2 suspicious axillary lymph node metastases on breast magnetic resonance imaging: upfront surgery vs. neoadjuvant chemotherapy
by: Seung Eun Lee, et al.
Published: (2023-05-01)

Tumor-Infiltrating Lymphocyte Level Consistently Correlates with Lower Stiffness Measured by Shear-Wave Elastography: Subtype-Specific Analysis of Its Implication in Breast Cancer
by: Na Lae Eun, et al.
Published: (2024-03-01)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
by: Sung Gwe Ahn, et al.
Published: (2018-03-01)

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer
by: Chang Ik Yoon, et al.
Published: (2020-04-01)

Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study
by: Soong June Bae, et al.
Published: (2024-04-01)

Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
by: Qiyou Wu, et al.
Published: (2023-01-01)

Lymphovascular invasion is an independent prognostic factor in breast cancer irrespective of axillary node metastasis and molecular subtypes
by: Suk Jun Lee, et al.
Published: (2023-11-01)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021-05-01)

Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer
by: Yangkyu Lee, et al.
Published: (2022-10-01)

Effects of Single Nucleotide Polymorphisms and Mediterranean Diet in Overweight or Obese Postmenopausal Women With Breast Cancer Receiving Adjuvant Hormone Therapy: A Pilot Randomized Controlled Trial
by: A-Ra Cho, et al.
Published: (2022-07-01)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
by: Soong June Bae, et al.
Published: (2021-08-01)

Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
by: Yoon Jin Cha, et al.
Published: (2022-09-01)

Prediction of a Multi-Gene Assay (Oncotype DX and Mammaprint) Recurrence Risk Group Using Machine Learning in Estrogen Receptor-Positive, HER2-Negative Breast Cancer—The BRAIN Study
by: Jung-Hwan Ji, et al.
Published: (2024-02-01)

Efficacy and safety of pegfilgrastim biosimilar MD‐110 in patients with breast cancer receiving chemotherapy: Single‐arm phase III
by: Toshimi Takano, et al.
Published: (2023-10-01)

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer
by: Eleni Triantafyllidi, et al.
Published: (2022-08-01)

On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
by: Chang Gon Kim, et al.
Published: (2023-01-01)

Knowledge, attitudes, and behaviors toward fertility preservation in patients with breast cancer: A cross-sectional survey of physicians
by: Soo Yeon Baek, et al.
Published: (2023-01-01)

Change in Shoulder Function in the Early Recovery Phase after Breast Cancer Surgery: A Prospective Observational Study
by: Jihee Min, et al.
Published: (2021-07-01)

Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer
by: Sung Gwe Ahn, et al.
Published: (2015-09-01)

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial
by: Abolghasem Allahyari, et al.
Published: (2022-09-01)

Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts
by: Sunyoung Park, et al.
Published: (2022-08-01)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
by: Alina Uifălean, et al.
Published: (2018-09-01)

Characteristics and chronologically changing patterns of late-onset breast cancer in Korean women of age ≥ 70 years: A hospital based-registry study
by: Hyun-June Paik, et al.
Published: (2022-12-01)

Effect of a 1-year tailored exercise program according to cancer trajectories in patients with breast cancer: study protocol for a randomized controlled trial
by: Jiin Ryu, et al.
Published: (2023-03-01)

First Experience in Korea of Stereotactic Partial Breast Irradiation for Low-Risk Early-Stage Breast Cancer
by: Won Hee Lee, et al.
Published: (2020-04-01)

Effects of Cortactin Expression on Prognosis in Patients with Breast Cancer
by: Hwangkyu Son, et al.
Published: (2023-09-01)

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer
by: Emma Franco-Mateos, et al.
Published: (2024-04-01)

Emerging role of biosimilars: Focus on trastuzumab and metastatic human epidermal growth factor receptor 2-positive breast cancer
by: Lyudmila U. Sarder, et al.
Published: (2023-12-01)